StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a report issued on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Stock Down 25.5 %
Shares of Bellerophon Therapeutics stock opened at $0.01 on Friday. Bellerophon Therapeutics has a twelve month low of $0.01 and a twelve month high of $0.02. The company’s 50 day moving average is $0.03 and its 200 day moving average is $0.04. The company has a market cap of $146,796.00, a price-to-earnings ratio of -0.01 and a beta of 0.74.
Bellerophon Therapeutics Announces Dividend
The company also recently disclosed a dividend, which was paid on Wednesday, December 18th. Investors of record on Friday, December 20th were issued a $0.019 dividend. This represents a dividend yield of 117.8%. The ex-dividend date was Thursday, December 19th.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Featured Articles
- Five stocks we like better than Bellerophon Therapeutics
- Energy and Oil Stocks Explained
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- 5 discounted opportunities for dividend growth investors
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- How to Calculate Return on Investment (ROI)
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
